{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-053593","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.430865+00:00","generated_at":"2026-06-16T04:56:47.407835+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VYNE Therapeutics licenses BD2-selective BET inhibitors, selects development candidate VYN202","bullets":["$3.75M upfront payment for exclusive worldwide license; up to $68.75M in milestones plus tiered royalties.","VYN202 is oral BD2-selective BET inhibitor for immuno-inflammatory conditions; IND-enabling studies ongoing.","Preclinical data suggests VYN202 may be best-in-class with potent anti-inflammatory and anti-fibrotic effects.","IND filing planned by year-end; VYNE expects to advance VYN202 into clinical development.","VYNE also obtained rights to additional BD2-selective BET inhibitor compounds from Tay Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-053593","json":"https://secwatch.observer/filing/0001104659-23-053593.json","markdown":"https://secwatch.observer/filing/0001104659-23-053593.md","text":"https://secwatch.observer/filing/0001104659-23-053593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923053593/0001104659-23-053593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923053593/tm2314020d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:56:47.407835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"665de39d3344e061940ff3813b06644f98b57471","claim":"VYNE Therapeutics Inc. entered into License Agreement with Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”) valued at up to an aggregate of $43.75 million (effective 2023-04-28).","evidence_excerpt":"On April 28, 2023, VYNE Therapeutics Inc. (the “Company”) and Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”) entered into a License Agreement (the “License Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923053593/0001104659-23-053593-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”)"},{"label":"Value","value":"up to an aggregate of $43.75 million"},{"label":"Effective","value":"2023-04-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}